Last reviewed · How we verify
Povidone-Iodine 1 % Topical Solution
At a glance
| Generic name | Povidone-Iodine 1 % Topical Solution |
|---|---|
| Sponsor | Shaare Zedek Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study (PHASE1)
- Evaluation of Emerging New Treatments for Infection Prevention in Total Joint Replacement (PHASE3)
- Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II) (PHASE3)
- SURGX Antimicrobial Gel Versus Povidone-iodine Skin Incision Prep in Total Shoulder Arthroplasty (PHASE4)
- Infection Prophylaxis in Total Joint Replacement (PHASE3)
- Base Curves of Bandage Contact Lenses and Their Effects on Post Trans-PRK Vision and Pain (NA)
- Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU) (PHASE3)
- Efficacy of Pyodine Soaked Gelfoam vs Single Topical Application of Clotrimazole in Otomycosis Treatment (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: